Detection and Management of Preeclampsia: Current Laboratory Testing and Emerging Biomarkers (Online CE Course)

Continuing Education Credits

P.A.C.E.® Contact Hours (acceptable for AMT, ASCP, and state recertification): 1 hour(s) Approved through 11/30/2025

Florida Board of Clinical Laboratory Personnel Credit Hours - General (Clinical Chemistry/UA/Toxicology): 1 hour(s) Approved through 11/30/2025

Objectives

• Define preeclampsia (PE) and discuss its prevalence, characteristics, signs, and symptoms.
• Identify the characteristics of mild and severe PE as well as the relationship to the HELLP Syndrome.
• Define the risk factors for PE and differentiate between eclampsia and the HELLP Syndrome.
• Describe the pathophysiology of PE, its cause, treatment, and prevention.
• Describe the main triggers used to diagnose PE.
• Identify laboratory tests used to assist in the diagnosis of PE.
• Define and describe angiogenesis relative to its possible role in PE and associated pro-angiogenic and anti-angiogenic factors.
• Describe the various potential biomarkers for identifying pregnant women at risk for PE.
• Identify assay methods available for several potential biomarkers.

Customer Ratings

(based on 337 customer ratings)

Course Outline

• Background and Overview of Preeclampsia
• Background and Overview
• Which of the following statements is NOT true in describing preeclampsia (PE)?
• Preeclampsia (PE) affects 5-10% of pregnant women and typically occurs after 20 weeks' gestation.
• Classification and Characteristics of Preeclampsia
• Classification and Characteristics of Preeclampsia (PE)
• HELLP Syndrome
• Which of the following can be defined as the presence of hypertension (blood pressure ≥ 140/90) on two occasions at least six hours apart but wi...
• What condition NOT attributable to any other disorder is associated with eclampsia?
• Which statement is TRUE regarding the HELLP syndrome?
• Risk Factors for Preeclampsia
• Risk Factors for Preeclampsia (PE)
• Which of the following are considered risk factors for PE?
• Pathophysiology of Preeclampsia
• Pathophysiology of Preeclampsia (PE)
• Doppler Ultrasonography of Uterine Arteries
• The pathophysiology of PE may be attributable to endothelial cell dysfunction in the ________________.
• Treatment and Prevention
• Treatment and Management of Preeclampsia (PE)
• Treatment and Management of PE, continued
• Treatment and Prevention (Aspirin Usage)
• Postpartum PE
• True or false? The only cure for PE is the delivery of the baby.
• Which statements are true regarding the use of aspirin to prevent PE?
• Current Laboratory Testing Used for PE Workup
• Laboratory Tests Used for PE Workup: Urine and Serum Chemistry
• Laboratory Tests Used for PE Workup: Hematology and Coagulation
• Which laboratory tests listed below are typically performed to assist in the diagnosis of PE, to establish baseline levels early in the disorder, and ...
• Emerging Biomarkers for Preeclampsia
• Emerging Biomarkers to Identify Risk for Preeclampsia (PE)
• Angiogenesis and Angiogenic Biomarkers
• Table I: Circulating Levels of Angiogenic Biomarkers in Preeclampsia (PE)
• Table II: Circulating Levels of Other Potential Biomarkers in Preeclampsia (PE).
• Laboratory Methods for Quantitation of Biomarkers Used for Determining Risk of PE
• New FDA-approved Biomarker Test System: The Thermo Scientific PlGF and sFlt-1 Test System.
• Angiogenesis is the physiological process through which new blood vessels form from pre-existing vessels.
• What statements are TRUE concerning angiogenesis and angiogenic biomarkers?
• PIGF acts as a vasodilator, increasing the diameter of existing arteries, and its serum levels have been found to be significantly lower in mild and s...
• Choose the correct answer regards the circulating levels of sFlt-1, sEng, and the sFlt-1/PIGF ratio in pregnant women with preeclampsia (PE).
• Which potential preeclampsia (PE) biomarker that is decreased in PE can be described as a glycoprotein, which is derived from the trophoblast cells an...
• Which potential PE biomarker is a cell surface molecule expressed by platelets and endothelial cells, and circulating levels are increased in PE?
• Which statements are true regards the Thermo Fisher Scientific Test System used to aid in the prognosis of PE with severe features in pregnant women?
• Summary and Conclusions
• American College of Obstetricians and Gynecologists (ACOG) Current Guidelines for Identifying Preeclampsia
• Summary and Conclusions on the Clinical Use of Biomarkers for Diagnosing and Predicting Risk for Developing PE
• National organizations such as ACOG typically do not include the use of biomarkers in the practice guidelines for diagnosing and identifying women wit...
• What conclusions can be made regarding the clinical use of biomarkers to identify and diagnose PE?
• References
• References

Additional Information